Clinical trial
A Phase 1, Open-Label, Adjuvant Dose-Escalation, Randomized Study to Evaluate the Safety and Immunogenicity of VBI-2901e, a Trivalent Coronavirus Vaccine Candidate Adjuvanted With Aluminum Phosphate and E6020 in Healthy Adults Previously Vaccinated With Licensed COVID-19 Vaccines
NCT05614245 is registered in ClinicalTrials.gov with VBI Vaccines Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label, Adjuvant Dose-Escalation, Randomized Study to Evaluate the Safety and Immunogenicity of VBI-2901e, a Trivalent Coronavirus Vaccine Candidate Adjuvanted With Aluminum Phosphate and E6020 in Healthy Adults Previously Vaccinated With Licensed COVID-19 Vaccines
- Lead sponsor
- VBI Vaccines Inc.
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- March 31, 2023
- Completion date
- June 30, 2024
- Enrollment
- 0 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.